Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,492 signal articles · 183 in last 24h · 116,679 total before filter · latest 28m ago
183last 24h
1708last 7d
279● bullish (7d)
149● bearish (7d)
205publishers
AllMacro321Earnings765M&A102Regulatory25Product16Analyst24
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Okta (OKTA) Is Considered a Good Investment by Brokers: Is That True?
Zacks6d agoneutral
Okta (OKTA) Is Considered a Good Investment by Brokers: Is That True?

According to the average brokerage recommendation (ABR), one should invest in Okta (OKTA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Is Carnival (CCL) a Buy as Wall Street Analysts Look Optimistic?
Zacks6d agobullish
Is Carnival (CCL) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Carnival (CCL) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Air taxi firm Joby acquires defense tech company for $500 million
Reuters6d agoneutral
Air taxi firm Joby acquires defense tech company for $500 million

Joby Aviation said on Tuesday it would buy defense technology ‌company Resonant Sciences for about $500 million, as ‌it looks to scale its business in a growing ​defense market. Electric vertical take-off and landing aircraft (eVTOL) companies are focusing more on the military market amid ramped-up defense spending driven by wars in ‌Ukraine and the ⁠Middle East. Here are some more details: • Shares of Santa Cruz, California-based Joby ⁠fell 6.5% in premarket trading.

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
24/7 Wall St.6d agoneutral
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?